CorMedix, Inc. (CRMD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.43-0.47%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CRMD
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||
| Revenues | 462.2 | 311.7 | 43.5 | — | 0.1 | 0.2 | 0.2 | 0.3 | 0.4 | 0.3 | 0.2 |
| Total Revenues | — | 311.7 | 43.5 | — | 0.1 | 0.2 | 0.2 | 0.3 | 0.4 | 0.3 | 0.2 |
| Cost of Revenues | — | 22.1 | 3.2 | — | 0.0 | 0.1 | 0.2 | 0.4 | 0.4 | 0.1 | 0.4 |
| Gross Profit | 382.6 | 275.7 | 40.3 | — | 0.1 | 0.0 | 0.0 | (0.1) | 0.0 | 0.2 | (0.1) |
| Operating Expenses & Income | |||||||||||
| Selling, General & Admin | — | — | — | 35.8 | 20.0 | 16.3 | 13.9 | 9.9 | — | — | — |
| R&D Expenses | 27.6 | 19.3 | 3.9 | 13.2 | 10.7 | 13.1 | 13.4 | 11.1 | 18.8 | 24.5 | 15.7 |
| Operating Income | 217.0 | 150.1 | (22.4) | (49.0) | (30.6) | (29.4) | (27.2) | (21.0) | (26.9) | (32.9) | (24.8) |
| Earnings from Continuing Operations | |||||||||||
| Interest Expense | — | 2.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 | 0.0 | 0.0 | 0.0 |
| Interest & Investment Income | — | 3.8 | 2.6 | 2.7 | — | — | 0.1 | 0.3 | 0.0 | 0.1 | 0.1 |
| Net Interest Expenses | — | — | — | (2.6) | — | — | (0.1) | 0.5 | (0.0) | (0.1) | (0.1) |
| Other Non-Operating Income / Expenses | (13.6) | (0.1) | 3.0 | 2.6 | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | 203.4 | 150.0 | (19.3) | (46.3) | (30.3) | (29.5) | (27.2) | (21.5) | (26.8) | (33.0) | (24.6) |
| Income Tax Expense | 16.2 | (13.0) | (1.4) | — | (0.6) | (1.3) | (5.2) | (5.1) | — | — | — |
| Earnings from Continuing Operations | — | — | — | (46.3) | (30.3) | — | — | — | — | — | — |
| Net Income | |||||||||||
| Minority Interest | — | — | — | — | — | 28.2 | 22.0 | — | — | — | — |
| Net Income | 187.2 | 163.1 | (17.9) | (46.3) | (29.7) | (28.2) | (22.0) | (16.4) | (26.8) | (33.0) | (24.6) |
| Per Share | |||||||||||
| Basic EPS | 2.39 | 2.25 | (0.30) | (0.91) | (0.74) | (0.75) | — | — | — | — | — |
| Diluted EPS | 2.02 | 2.04 | (0.30) | (0.91) | (0.74) | (0.75) | — | — | — | — | — |
| Revenue per Share | 5.00 | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 78.4 | 0.1 | 58.9 | 50.9 | 40.3 | 37.7 | — | — | — | — | — |
| Diluted Weighted Avg Shares | 92.5 | 0.1 | 58.9 | 50.9 | 40.3 | 37.7 | — | — | — | — | — |
| Supplemental | |||||||||||
| EBIT | 217.0 | 150.1 | (22.4) | (49.0) | (30.6) | (29.4) | (27.2) | (21.0) | (26.9) | (32.9) | (24.8) |
| Effective Tax Rate | 8.0% | — | — | — | 1.9% | 4.2% | 19.0% | 23.5% | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.